Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Levofloxacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP
Details : Levaquin-Generic (levofloxacin) is a fluoroquinolone antibiotic used to treat infections caused by bacteria. It is indicated for the treatment of pneumonia, acute bacterial sinusitis.
Brand Name : Levaquin-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 27, 2024
Lead Product(s) : Levofloxacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Levofloxacin,Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
7-day Levofloxacin/Dexamethasone Eye Drops as Effective as Standard Treatment After Cataract Surgery
Details : The study demonstrated for the first time that 7-day levofloxacin/dexamethasone eye drops were as effective as 14-day tobramycin/dexamethasone eye drops to treat ocular inflammation and prevent infection in post-cataract surgery patients.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 13, 2020
Lead Product(s) : Levofloxacin,Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Levofloxacin,Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Taro Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Licensing Agreement
NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical Industries
Details : NTC Srl has granted exclusive license and distribution rights to one of its R&D products to Taro Pharmaceutical. The product combines a quinolone antibiotic with an anti-inflammatory steroid in eye drops intended to provide an appropriate treatment for p...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 17, 2020
Lead Product(s) : Levofloxacin,Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Taro Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?